More Moderna vaccine shots on the way

5 January 2021
moderna_therapeutics_large

mRNA vaccine specialist Moderna (Nasdaq: MRNA) has upped its global production estimate for its novel coronavirus vaccine, mRNA-1273.

The USA-based firm had previously said it expected to be able to produce 500 million doses, but continued investment in infrastructure and staff will allow at least 600 million doses, it believes.

For the full year, if all goes well, Moderna said it may be able to expand supply further, to as much as one billion doses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology